Crinetics Pharmaceuticals Inc. (CRNX), which reported positive results from its phase III PATHFNDR-1 study last September, is expected to report phase III PATHFNDR-2 study topline data this quarter.
The company's lead drug candidate is Paltusotine, a new class of oral, selective, nonpeptide, somatostatin receptor type 2 (SST2) agonist designed for the treatment of acromegaly.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.